A study of more than 8 million adults in Ontario, Canada suggests that even a modest loss of kidney function is associated with increased health risks. The study, published in The BMJ, could lead to better approaches to prevent chronic kidney disease and related conditions, particularly in younger adults.
Credit: The Ottawa Hospital
A study of more than 8 million adults in Ontario, Canada suggests that even a modest loss of kidney function is associated with increased health risks. The study, published in The BMJ, could lead to better approaches to prevent chronic kidney disease and related conditions, particularly in younger adults.
“The dogma is that healthy, young adults don’t need to worry about kidney function unless it drops to around 50% of the normal level, but our research suggests that even a more modest 20-30% drop may have consequences and we may want to have earlier conversations about prevention and monitoring,” said senior author Dr. Manish Sood, senior scientist, nephrologist and Jindal Research Chair for the Prevention of Kidney Disease at The Ottawa Hospital and professor at the University of Ottawa.
The research team examined ICES health record data from 2008 to 2021 for every Ontario adult aged 18-65 who had at least one blood test for kidney function, but no history of kidney disease. They found that 18% of those in the 18-39 age group had kidney function that was modestly below normal levels, but not low enough to be diagnosed with chronic kidney disease. Individuals in this “grey zone” faced a modestly increased risk of kidney failure, death and cardiovascular events such as heart attack.
For example, in young adults (age 18-39), a 20-30% loss in kidney function was associated with a 1.4-fold increase in death, 1.3-fold increase in a cardiac event and a 6-fold increase in the risk of kidney failure. However, the absolute risk of any of these events was still low at less than 2 per 1000.
“Thankfully, the absolute risk for any one individual with kidney function in this grey zone is low, but when we look at the whole population, the impact could be quite significant,” said co-senior author Dr. Greg Knoll, senior scientist, nephrologist and Head of the Department of Medicine at The Ottawa Hospital and the University of Ottawa. “We need further research to confirm these findings and then see if we can reduce the risk through lifestyle modification.”
While the test for kidney function (blood creatine) is relatively inexpensive and readily available, the researchers are not suggesting routine testing for all individuals at this time. However, if an individual has had a kidney test that shows a modest reduction in function, it can be a catalyst for a conversation with a health care provider. All individuals can also reduce their risk of kidney disease by eating a healthy diet with lower salt, exercising regularly and limiting alcohol intake.
Dr. Sood and his colleagues previously developed the Project BigLife Chronic Kidney Disease calculator to help individuals calculate their kidney disease risk and see the impact of lifestyle changes. The calculator will continue to be refined as new research arises.
Full reference: Associations between modest reductions in kidney function and adverse outcomes in young adults: retrospective, population based cohort study. Junayd Hussain, Nicholas Grubic, Ayub Akbari, Mark Canney, Meghan J Elliott, Pietro Ravani, Peter Tanuseputro, Edward G Clark, Gregory L Hundemer, Tim Ramsay, Navdeep Tangri, Greg A Knoll, Manish M Sood. BMJ 2023;381:e075062. http://dx.doi.org/10.1136/bmj‑2023‑075062
Funding: The Ottawa Hospital Academic Medical Organization, The Ottawa Hospital, Jindal Research Chair for the Prevention of Kidney Disease (funded through The Ottawa Hospital Foundation).
Media contact: Jenn Ganton, [email protected], 613-614-5253
The Ottawa Hospital (TOH) is one of Canada’s top learning and research hospitals where we are guided by our vision to provide the world-class and compassionate care we would all want for our loved ones. Our multi-campus hospital, affiliated with the University of Ottawa, is home to the Regional Trauma Centre and Cancer Centre, and to discoveries that are adopted globally. Backed by generous support from the community, we are focused on reshaping the future of health care to improve the health of our diverse population of patients from Eastern Ontario, Western Quebec, and Nunavut. For more information about research at The Ottawa Hospital, visit www.ohri.ca.
ICES is an independent, non-profit research institute that uses population-based health information to produce knowledge on a broad range of healthcare issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting healthcare needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. For the latest ICES news, follow us on Twitter: @ICESOntario
The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe. www.uottawa.ca
Journal
The BMJ
DOI
10.1136/bmj‑2023‑075062
Method of Research
Observational study
Subject of Research
People
Article Title
Associations between modest reductions in kidney function and adverse outcomes in young adults: retrospective, population based cohort study
Article Publication Date
23-Jun-2023
COI Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare support from Institute of Clinical Evaluative Sciences. MMS has received consultancy fees from AstraZeneca, Bayer, Otsuka, and GlaxoSmithKline. Besides this, all authors declare no support from any
organisation for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
